Drug intelligence / Profile preview

LYN-045

Development stage: Unknown
Lead developer: Innoviva
Modality: Small Molecules
Administration: Oral

Overview

LYN-045 is an investigational once-weekly extended-release (ER) oral capsule formulation of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Developed by Lyndra Therapeutics using its proprietary LYNX drug delivery platform (originally licensed from MIT), LYN-045 is designed to reside in the stomach and provide continuous, steady release of dapagliflozin over a seven-day period. This once-weekly dosing regimen aims to improve medication adherence and glycemic control in patients with type 2 diabetes mellitus compared to daily immediate-release formulations. Sun Pharma holds an exclusive license to manufacture and market LYN-045 in six countries, including India and Brazil, pending further clinical development.

Other names: dapagliflozin extended-releaseonce-weekly dapagliflozin

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on LYN-045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYN-045.